IL242885B - Deficient adenosine monophosphate cyclic-adenylyl cyclase and preparations and methods for treating heart failure and increasing heart function - Google Patents

Deficient adenosine monophosphate cyclic-adenylyl cyclase and preparations and methods for treating heart failure and increasing heart function

Info

Publication number
IL242885B
IL242885B IL242885A IL24288515A IL242885B IL 242885 B IL242885 B IL 242885B IL 242885 A IL242885 A IL 242885A IL 24288515 A IL24288515 A IL 24288515A IL 242885 B IL242885 B IL 242885B
Authority
IL
Israel
Prior art keywords
incompetent
compositions
methods
heart failure
cardiac function
Prior art date
Application number
IL242885A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of IL242885B publication Critical patent/IL242885B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51Lyases (4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y406/00Phosphorus-oxygen lyases (4.6)
    • C12Y406/01Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01001Aodenylate cyclase (4.6.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL242885A 2013-06-07 2015-12-02 Deficient adenosine monophosphate cyclic-adenylyl cyclase and preparations and methods for treating heart failure and increasing heart function IL242885B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361832759P 2013-06-07 2013-06-07
PCT/US2014/040948 WO2014197624A1 (en) 2013-06-07 2014-06-04 Cycle adenosine monophosphate-incompetent adenylyl cyclase and compositions and methods for treating heart failure and increasing cardiac function

Publications (1)

Publication Number Publication Date
IL242885B true IL242885B (en) 2019-12-31

Family

ID=52008569

Family Applications (1)

Application Number Title Priority Date Filing Date
IL242885A IL242885B (en) 2013-06-07 2015-12-02 Deficient adenosine monophosphate cyclic-adenylyl cyclase and preparations and methods for treating heart failure and increasing heart function

Country Status (14)

Country Link
US (1) US11040091B2 (enExample)
EP (1) EP3004343B1 (enExample)
JP (1) JP6571069B2 (enExample)
KR (1) KR20160032090A (enExample)
CN (1) CN105452458A (enExample)
AU (1) AU2014274902B2 (enExample)
BR (1) BR112015030355A8 (enExample)
CA (1) CA2914029A1 (enExample)
DK (1) DK3004343T3 (enExample)
HK (1) HK1222884A1 (enExample)
IL (1) IL242885B (enExample)
RU (1) RU2015155831A (enExample)
WO (1) WO2014197624A1 (enExample)
ZA (1) ZA201508942B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10293059B2 (en) * 2015-04-09 2019-05-21 Cornell University Gene therapy to prevent reactions to allergens
WO2018080146A2 (ko) * 2016-10-24 2018-05-03 광주과학기술원 단백질 탈 인산화 효소 1 억제 펩타이드를 포함하는 혈관 질환 치료용 조성물
WO2018090036A1 (en) * 2016-11-14 2018-05-17 Renova Therapeutics, Inc. Method of protection for cardiac tissue
US11760987B2 (en) 2017-09-07 2023-09-19 The Regents Of The University Of California Compositions and methods for the treatment or prevention of heart failure
CN111542334B (zh) * 2017-09-29 2024-01-23 贝特基因 用于预防或治疗心律失常的药物组合物
JP2021526818A (ja) * 2018-06-08 2021-10-11 ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. 心筋症のためのaav心臓遺伝子治療
CN109010799B (zh) * 2018-07-09 2021-07-06 沣潮医药科技(上海)有限公司 RyR2蛋白或RyR2重组蛋白在制备抗心力衰竭药物中的用途
CN109191052B (zh) * 2018-10-22 2020-09-25 山东大学 一种多车型车辆路径优化方法、服务器及系统
CA3189740A1 (en) 2020-07-27 2022-02-03 Anjarium Biosciences Ag Compositions of dna molecules, methods of making therefor, and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1255822A2 (en) * 1999-12-27 2002-11-13 The Regents Of The University Of California Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure

Also Published As

Publication number Publication date
US11040091B2 (en) 2021-06-22
ZA201508942B (en) 2019-05-29
AU2014274902B2 (en) 2020-06-04
DK3004343T3 (en) 2019-02-04
JP2016521708A (ja) 2016-07-25
EP3004343A1 (en) 2016-04-13
CA2914029A1 (en) 2014-12-11
WO2014197624A1 (en) 2014-12-11
RU2015155831A (ru) 2017-07-14
AU2014274902A1 (en) 2015-12-24
RU2015155831A3 (enExample) 2018-03-28
KR20160032090A (ko) 2016-03-23
EP3004343B1 (en) 2018-10-10
BR112015030355A2 (pt) 2017-07-25
JP6571069B2 (ja) 2019-09-04
BR112015030355A8 (pt) 2019-12-24
CN105452458A (zh) 2016-03-30
US20160101164A1 (en) 2016-04-14
HK1222884A1 (zh) 2017-07-14
EP3004343A4 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
ZA201508942B (en) Cycle adenosine monophosphate-incompetent adenylyl cyclase and compositions and methods for treating heart failure and increasing cardiac function
IL323967A (en) Pyrimidinedione compounds against cardiac disorders
ZA201601146B (en) Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug
SI3294283T1 (sl) Režim odmerjanja sakubitril-valsartan za zdravljenje srčnega popuščanja
ZA201507045B (en) Uridine nucleoside derivatives, compositions and methods of use
PL3038656T3 (pl) Związek glikozaminoglikanu, sposób wytwarzania i jego zastosowania
IL239986A0 (en) A self-assembling structure that can be disassembled
PL3041831T3 (pl) Postacie soli alfa-TEA: kompozycje i zastosowania do leczenia choroby
GB201414330D0 (en) Improvements to analysing physiological electrograms
EP2953631A4 (en) Methods of treating heart failure
GB201520081D0 (en) Improvements in or relating to pouches
IL245675A0 (en) Therapeutic regimen and method for treating type 2 diabetes
GB201302096D0 (en) NOvel cyclic compounds and improved treatments for cardiac and cardiovascular disease
GB201516314D0 (en) Evaluation method for vascular hyperpermeability regulation action
GB201320032D0 (en) Novel methods for increasing heart contractility and preventing heart failure
GB201307903D0 (en) Rapid method to Diagnosis Hepatitis
GB201402288D0 (en) Novel cyclic compounds and improved treatments for cardiac and cardiovascular disease
GB201300697D0 (en) Muscle stimulation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed